Samrat Pharmachem（530125）株式概要Samrat Pharmachem Limited はインドで医薬化学品の製造販売を行っている。 詳細530125 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より67.3%で取引されている リスク分析過去5年間で収益は年間22.6%減少しました。 意味のある時価総額がありません ( ₹694M )すべてのリスクチェックを見る530125 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹224.5586.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-17m4b2016201920222025202620282031Revenue ₹4.5bEarnings ₹417.8mAdvancedSet Fair ValueView all narrativesSamrat Pharmachem Limited 競合他社Retina PaintsSymbol: BSE:543902Market cap: ₹785.4mKemistarSymbol: BSE:531163Market cap: ₹666.0mBhatia Colour ChemSymbol: BSE:543497Market cap: ₹717.1mSrivasavi Adhesive TapesSymbol: NSEI:SRIVASAVIMarket cap: ₹739.9m価格と性能株価の高値、安値、推移の概要Samrat Pharmachem過去の株価現在の株価₹224.5552週高値₹420.0052週安値₹190.00ベータ-0.371ヶ月の変化2.58%3ヶ月変化11.16%1年変化-39.31%3年間の変化-54.80%5年間の変化1.40%IPOからの変化4,391.00%最新ニュースお知らせ • Mar 25Samrat Pharmachem Limited to Report Fiscal Year 2026 Results on May 30, 2026Samrat Pharmachem Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹1.49 loss per share (vs ₹9.01 profit in 3Q 2025)Third quarter 2026 results: ₹1.49 loss per share (down from ₹9.01 profit in 3Q 2025). Revenue: ₹638.3m (flat on 3Q 2025). Net loss: ₹4.60m (down 117% from profit in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.Buy Or Sell Opportunity • Feb 10Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ₹245. The fair value is estimated to be ₹204, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 71%.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹238, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 57% over the past three years.お知らせ • Dec 29Samrat Pharmachem Limited to Report Q3, 2026 Results on Feb 13, 2026Samrat Pharmachem Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Nov 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹842.1m market cap, or US$9.50m). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).最新情報をもっと見るRecent updatesお知らせ • Mar 25Samrat Pharmachem Limited to Report Fiscal Year 2026 Results on May 30, 2026Samrat Pharmachem Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹1.49 loss per share (vs ₹9.01 profit in 3Q 2025)Third quarter 2026 results: ₹1.49 loss per share (down from ₹9.01 profit in 3Q 2025). Revenue: ₹638.3m (flat on 3Q 2025). Net loss: ₹4.60m (down 117% from profit in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.Buy Or Sell Opportunity • Feb 10Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ₹245. The fair value is estimated to be ₹204, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 71%.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹238, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 57% over the past three years.お知らせ • Dec 29Samrat Pharmachem Limited to Report Q3, 2026 Results on Feb 13, 2026Samrat Pharmachem Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Nov 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹842.1m market cap, or US$9.50m). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹879.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 4.3% per year over the past 5 years. Market cap is less than US$10m (₹879.9m market cap, or US$9.97m). Minor Risk Paying a dividend despite having no free cash flows.お知らせ • Sep 27Samrat Pharmachem Limited Appoints Piyush Dharod as Non-Executive Independent DirectorSamrat Pharmachem Limited at its AGM held on September 25, 2025, approved appointment of Mr. Piyush Dharod (DIN: 11119391) as Non-Executive Independent Director of the Company.お知らせ • Sep 26Samrat Pharmachem Limited to Report Q2, 2026 Results on Nov 14, 2025Samrat Pharmachem Limited announced that they will report Q2, 2026 results on Nov 14, 2025Upcoming Dividend • Sep 11Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 18 September 2025. Payment date: 24 October 2025. Payout ratio is a comfortable 4.3% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Aug 15First quarter 2026 earnings released: ₹0.74 loss per share (vs ₹6.69 profit in 1Q 2025)First quarter 2026 results: ₹0.74 loss per share (down from ₹6.69 profit in 1Q 2025). Revenue: ₹763.4m (down 6.2% from 1Q 2025). Net loss: ₹2.29m (down 111% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance.お知らせ • Jul 02Samrat Pharmachem Limited Announces Resignation of Renu Dharod as Director, Effective 30 June 2025Samrat Pharmachem Limited announced that Ms. Renu Dharod (DIN: 07063088), has tendered her resignation as the Independent Director of the Company, with effect from close of business hours on 30th June, 2025, citing pre-occupation and other personal commitments. Consequently, she shall also cease to be the Chairman of the Corporate Social Responsibility Committee, Stakeholders Relationship Committee and Risk Management Committee and Member of the Audit Committee, Nomination & Remuneration Committee & Health, Safety and Sustainability Committee of the Company.お知らせ • Jun 23Samrat Pharmachem Limited to Report Q1, 2026 Results on Aug 13, 2025Samrat Pharmachem Limited announced that they will report Q1, 2026 results on Aug 13, 2025お知らせ • Jun 02Samrat Pharmachem Limited, Annual General Meeting, Sep 25, 2025Samrat Pharmachem Limited, Annual General Meeting, Sep 25, 2025.New Risk • Jun 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.7m).Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹23.02 (vs ₹7.00 in FY 2024)Full year 2025 results: EPS: ₹23.02 (up from ₹7.00 in FY 2024). Revenue: ₹2.87b (up 1.8% from FY 2024). Net income: ₹71.1m (up 229% from FY 2024). Profit margin: 2.5% (up from 0.8% in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.お知らせ • May 30Samrat Pharmachem Limited Recommends Dividend for Fiscal Year 2024-25, Payable on or Before October 24, 2025Samrat Pharmachem Limited at its meeting held on May 30, 2025 recommended Dividend at 10% on paid-up capital of the company. Record Date: September 18, 2025, The Company has fixed September 18, 2025, as the Record Date for the purpose of determining the Members eligible to receive dividend of INR 1.00 per equity share for Fiscal Year 2024-25. The dividend, if approved at the 33rd Annual General Meeting, shall be paid on or before October 24, 2025.Valuation Update With 7 Day Price Move • May 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹390, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 26x in the Chemicals industry in India. Negligible returns to shareholders over past three years.Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹405, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 22% over the past three years.お知らせ • Mar 26Samrat Pharmachem Limited to Report Fiscal Year 2025 Results on May 30, 2025Samrat Pharmachem Limited announced that they will report fiscal year 2025 results on May 30, 2025Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹386, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 16% over the past three years.Reported Earnings • Feb 15Third quarter 2025 earnings released: EPS: ₹9.01 (vs ₹1.11 in 3Q 2024)Third quarter 2025 results: EPS: ₹9.01 (up from ₹1.11 in 3Q 2024). Revenue: ₹636.7m (up 3.2% from 3Q 2024). Net income: ₹27.8m (up ₹24.4m from 3Q 2024). Profit margin: 4.4% (up from 0.6% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Dec 31Samrat Pharmachem Limited to Report Fiscal Year 2024 Results on Feb 14, 2025Samrat Pharmachem Limited announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹8.61 (vs ₹0.61 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹8.61 (up from ₹0.61 loss in 2Q 2024). Revenue: ₹706.6m (down 11% from 2Q 2024). Net income: ₹26.6m (up ₹28.5m from 2Q 2024). Profit margin: 3.8% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Sep 27Samrat Pharmachem Limited to Report First Half, 2025 Results on Nov 14, 2024Samrat Pharmachem Limited announced that they will report first half, 2025 results on Nov 14, 2024New Risk • Sep 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (1.2% net profit margin). Market cap is less than US$100m (₹1.71b market cap, or US$20.5m).Buy Or Sell Opportunity • Sep 16Now 27% overvalued after recent price riseOver the last 90 days, the stock has risen 86% to ₹632. The fair value is estimated to be ₹498, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 33%.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹506, the stock trades at a trailing P/E ratio of 43.2x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 152% over the past three years.お知らせ • Sep 04Samrat Pharmachem Limited Proposes Dividend for Fiscal Year 2023-24, Payable on or Before October 25, 2024Samrat Pharmachem Limited has fixed September 19, 2024, as the Record Date for the purpose of determining the Members eligible to receive dividend of INR 1.00/- per equity share for FY2023-24. The dividend, if approved at the 32nd Annual General Meeting, shall be paid on or before October 25, 2024.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹462, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 133% over the past three years.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹6.68 (vs ₹1.98 in 1Q 2024)First quarter 2025 results: EPS: ₹6.68 (up from ₹1.98 in 1Q 2024). Revenue: ₹814.1m (up 42% from 1Q 2024). Net income: ₹20.7m (up 238% from 1Q 2024). Profit margin: 2.5% (up from 1.1% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.お知らせ • Jul 05Samrat Pharmachem Limited Announces Director ResignationsSamrat Pharmachem Limited informed about the following changes composition of the Board: Mr. Mahendra Pipalia (DIN: 00216959), has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on 28th June, 2024, citing pre-occupation and other personal commitments. Consequently, he shall also cease to be the Chairman of the Audit Committee and Member of the Nomination & Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, Corporate Social Responsibility Committee & Health, Safety and Sustainability Committee of the Company. Mr. Samir Kothary (DIN: 00216603), has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on 28th June, 2024, citing pre-occupation and other personal commitments. Consequently, he shall also cease to be the Chairman of the Nomination & Remuneration Committee, Health, Safety and Sustainability Committee and Member of the Audit Committee, Stakeholders Relationship Committee, Risk Management Committee and Corporate Social Responsibility Committee of the Company.お知らせ • Jun 30Samrat Pharmachem Limited to Report Q1, 2025 Results on Aug 13, 2024Samrat Pharmachem Limited announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹7.00 (vs ₹53.83 in FY 2023)Full year 2024 results: EPS: ₹7.00 (down from ₹53.83 in FY 2023). Revenue: ₹2.83b (down 8.9% from FY 2023). Net income: ₹21.6m (down 87% from FY 2023). Profit margin: 0.8% (down from 5.4% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Declared Dividend • Jun 01Dividend of ₹1.00 announcedDividend of ₹1.00 is the same as last year. Ex-date: 19th September 2024 Payment date: 26th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (2% earnings payout ratio) and cash flows (5% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 98% to shift the payout ratio to a potentially unsustainable range, which is more than the 53% EPS decline seen over the last 5 years.お知らせ • May 31Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024.お知らせ • Mar 29Samrat Pharmachem Limited to Report Q4, 2024 Results on May 30, 2024Samrat Pharmachem Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 30, 2024Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹1.11 (vs ₹6.78 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.11 (down from ₹6.78 in 3Q 2023). Revenue: ₹620.9m (down 26% from 3Q 2023). Net income: ₹3.44m (down 84% from 3Q 2023). Profit margin: 0.6% (down from 2.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Dec 30Samrat Pharmachem Limited to Report Q3, 2023 Results on Feb 14, 2024Samrat Pharmachem Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2024Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹0.61 loss per share (vs ₹19.14 profit in 2Q 2023)Second quarter 2024 results: ₹0.61 loss per share (down from ₹19.14 profit in 2Q 2023). Revenue: ₹800.4m (up 13% from 2Q 2023). Net loss: ₹1.88m (down 103% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 27Samrat Pharmachem Limited to Report Q2, 2024 Results on Nov 08, 2023Samrat Pharmachem Limited announced that they will report Q2, 2024 results on Nov 08, 2023Upcoming Dividend • Sep 11Upcoming dividend of ₹1.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 18 September 2023. Payment date: 24 October 2023. Payout ratio is a comfortable 1.9% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹418, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years.Reported Earnings • Aug 15First quarter 2024 earnings released: EPS: ₹1.98 (vs ₹30.32 in 1Q 2023)First quarter 2024 results: EPS: ₹1.98 (down from ₹30.32 in 1Q 2023). Revenue: ₹578.4m (down 33% from 1Q 2023). Net income: ₹6.11m (down 94% from 1Q 2023). Profit margin: 1.1% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year whereas the company’s share price has increased by 57% per year.Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹363, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 316% over the past three years.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹508, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 446% over the past three years.お知らせ • Jul 01Samrat Pharmachem Limited to Report Q1, 2024 Results on Aug 14, 2023Samrat Pharmachem Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹53.83 (vs ₹55.62 in FY 2022)Full year 2023 results: EPS: ₹53.83 (down from ₹55.62 in FY 2022). Revenue: ₹3.11b (up 40% from FY 2022). Net income: ₹166.3m (down 3.2% from FY 2022). Profit margin: 5.3% (down from 7.7% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jun 01Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2023Samrat Pharmachem Limited at its board meeting held on May 30, 2023, recommended dividend of INR 1 per fully paid equity share of INR 10 each (10%) for the financial year ended March 31, 2023, subject to approval of the members at the upcoming Annual General Meeting of the Company.お知らせ • May 31Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023. Agenda: Annual General Meeting.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹430, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 420% over the past three years.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹408, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 575% over the past three years.Reported Earnings • Feb 18Third quarter 2023 earnings released: EPS: ₹6.78 (vs ₹20.87 in 3Q 2022)Third quarter 2023 results: EPS: ₹6.78 (down from ₹20.87 in 3Q 2022). Revenue: ₹839.9m (up 52% from 3Q 2022). Net income: ₹21.0m (down 68% from 3Q 2022). Profit margin: 2.5% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Dec 30Samrat Pharmachem Limited to Report Q4, 2022 Results on Feb 14, 2023Samrat Pharmachem Limited announced that they will report Q4, 2022 results at 3:30 PM, Indian Standard Time on Feb 14, 2023Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹869, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 842% over the past three years.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹768, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 697% over the past three years.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Independent Executive Director Megh Mehta was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 01Samrat Pharmachem Limited to Report Q2, 2023 Results on Nov 14, 2022Samrat Pharmachem Limited announced that they will report Q2, 2023 results on Nov 14, 2022Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹1,156, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,286% over the past three years.Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹885, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 996% over the past three years.お知らせ • Sep 03Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022, at 14:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹545, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 587% over the past three years.お知らせ • Jul 01Samrat Pharmachem Limited to Report Q1, 2023 Results on Aug 13, 2022Samrat Pharmachem Limited announced that they will report Q1, 2023 results on Aug 13, 2022Reported Earnings • Jun 01Full year 2022 earnings released: EPS: ₹55.62 (vs ₹17.26 in FY 2021)Full year 2022 results: EPS: ₹55.62 (up from ₹17.26 in FY 2021). Revenue: ₹2.22b (up 24% from FY 2021). Net income: ₹171.8m (up 222% from FY 2021). Profit margin: 7.7% (up from 3.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 31Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2022Samrat Pharmachem Limited recommended dividend of INR 1/- per fully paid equity share of INR 10/- for the financial year ended March 31, 2022, subject to approval of members at the upcoming annual general meeting of the company.Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹431, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 412% over the past three years.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Independent Executive Director Megh Mehta was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 09Samrat Pharmachem Limited to Report Q4, 2022 Results on May 30, 2022Samrat Pharmachem Limited announced that they will report Q4, 2022 results on May 30, 2022Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹20.87 (up from ₹4.97 in 3Q 2021). Revenue: ₹553.4m (flat on 3Q 2021). Net income: ₹64.5m (up 320% from 3Q 2021). Profit margin: 12% (up from 2.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jan 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹426, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 608% over the past three years.Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹318, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 525% over the past three years.Reported Earnings • Nov 18Second quarter 2022 earnings released: EPS ₹9.03 (vs ₹4.66 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹591.5m (up 43% from 2Q 2021). Net income: ₹27.9m (up 94% from 2Q 2021). Profit margin: 4.7% (up from 3.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹189, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 109% over the past three years.Reported Earnings • Aug 18First quarter 2022 earnings released: EPS ₹3.09 (vs ₹2.58 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹473.9m (up 34% from 1Q 2021). Net income: ₹9.54m (up 20% from 1Q 2021). Profit margin: 2.0% (down from 2.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 30% per year.Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹278, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 114% over the past three years.Reported Earnings • Jul 03Full year 2021 earnings released: EPS ₹17.26 (vs ₹13.71 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹1.79b (up 30% from FY 2020). Net income: ₹53.3m (up 26% from FY 2020). Profit margin: 3.0% (down from 3.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 22% per year.Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₹187, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 23% over the past three years.Is New 90 Day High Low • Mar 01New 90-day high: ₹152The company is up 15% from its price of ₹133 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹145, the stock is trading at a trailing P/E ratio of 14.5x, up from the previous P/E ratio of 12.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years were flat.Reported Earnings • Feb 14Third quarter 2021 earnings released: EPS ₹4.97 (vs ₹1.52 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹549.4m (up 56% from 3Q 2020). Net income: ₹15.4m (up 226% from 3Q 2020). Profit margin: 2.8% (up from 1.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Jan 14Samrat Pharmachem Limited to Report Q3, 2021 Results on Feb 13, 2021Samrat Pharmachem Limited announced that they will report Q3, 2021 results on Feb 13, 2021お知らせ • Dec 05Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020, at 13:00 Indian Standard Time. Agenda: To consider and receive the audited financial statements of the company for the year ended 31 March 2020, together with directors' and auditors' reports thereon; to consider re-appointments of directors in place of Mr. Megh Rajesh Mehta (DIN: 07287394), who retires by rotation and, being eligible, offers himself for re-appointment; and to consider other matters.Is New 90 Day High Low • Dec 01New 90-day high: ₹133The company is up 24% from its price of ₹107 on 02 September 2020. The Indian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Dec 01Market bids up stock over the past weekAfter last week's 15% share price gain to ₹133, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years are 67%.Reported Earnings • Nov 16Second quarter 2021 earnings released: EPS ₹4.66The company reported a soft second quarter result with weaker earnings and profit margins, although revenues were improved. Second quarter 2021 results: Revenue: ₹415.2m (up 12% from 2Q 2020). Net income: ₹14.4m (down 4.2% from 2Q 2020). Profit margin: 3.5% (down from 4.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 26Market bids up stock over the past weekAfter last week's 16% share price gain to ₹130, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 11x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 81%.お知らせ • Sep 09Samrat Pharmachem Limited to Report Q1, 2020 Results on Sep 14, 2020Samrat Pharmachem Limited announced that they will report Q1, 2020 results on Sep 14, 2020お知らせ • Jul 18Samrat Pharmachem Limited to Report Fiscal Year 2020 Results on Jul 31, 2020Samrat Pharmachem Limited announced that they will report fiscal year 2020 results on Jul 31, 2020株主還元530125IN ChemicalsIN 市場7D7.2%0.3%0.5%1Y-39.3%-2.9%-0.5%株主還元を見る業界別リターン: 530125過去 1 年間で-2.9 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: 530125は、過去 1 年間で-0.5 % のリターンを上げたIndian市場を下回りました。価格変動Is 530125's price volatile compared to industry and market?530125 volatility530125 Average Weekly Movement7.0%Chemicals Industry Average Movement7.3%Market Average Movement7.1%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: 530125 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 530125の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199228Lalit Mehtawww.samratpharmachem.comSamrat Pharmachem Limited はインドで医薬化学品の製造・販売を行っている。ヨウ化3-5-ジ、ヨウ化アンモニウム、ヨウ化カドミウム、ヨウ化カルシウム、ヨウ化クリオキノール、ヨウ化銅、ヨウ化エチル、ヨウ化エチレンジアミン、ヨウ化水素酸、ヨウ素酸、ヨウ素、一塩化ヨウ素、ヨードキノール、ヨウ化リチウム、ヨウ化メチル、ヨウ化コハク酸イミド、ヨウ化カリウム、ヨウ化カリウム、ヨウ化コハク酸イミド、ヨウ化メチル、ヨウ化コハク酸イミド、ヨウ化コハク酸イミド、ヨウ化カリウムヨウ化メチル、ヨウ化コハク酸イミド、ヨウ化過ヨウ素酸、ヨウ化カリウム、ヨウ化メタ過ヨウ素酸カリウム、ポビドンヨード、二酸化セレン、ヨウ化ナトリウム、ヨウ化ナトリウム、ヨウ化メタ過ヨウ素酸ナトリウム、亜セレン酸ナトリウム、ヨウ化トリメチルスルホキソニウム。同社は、農薬、動物飼料、化学、化粧品、食品、LCDスクリーン、造影剤、製薬、スクリーン印刷、ナイロン繊維、タイヤコード製造などの業界に製品を供給している。また、製品を米国、欧州、アフリカ、アジア、中東、および海外に輸出している。Samrat Pharmachem Limitedは1992年に設立され、インドのムンバイを拠点としている。もっと見るSamrat Pharmachem Limited 基礎のまとめSamrat Pharmachem の収益と売上を時価総額と比較するとどうか。530125 基礎統計学時価総額₹693.79m収益（TTM）-₹16.75m売上高(TTM)₹2.89b0.2xP/Sレシオ-41.4xPER（株価収益率530125 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計530125 損益計算書（TTM）収益₹2.89b売上原価₹2.81b売上総利益₹81.14mその他の費用₹97.89m収益-₹16.75m直近の収益報告Dec 31, 2025次回決算日May 30, 2026一株当たり利益（EPS）-5.42グロス・マージン2.81%純利益率-0.58%有利子負債／自己資本比率15.5%530125 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.4%現在の配当利回り4%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 21:14終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Samrat Pharmachem Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 25Samrat Pharmachem Limited to Report Fiscal Year 2026 Results on May 30, 2026Samrat Pharmachem Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹1.49 loss per share (vs ₹9.01 profit in 3Q 2025)Third quarter 2026 results: ₹1.49 loss per share (down from ₹9.01 profit in 3Q 2025). Revenue: ₹638.3m (flat on 3Q 2025). Net loss: ₹4.60m (down 117% from profit in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
Buy Or Sell Opportunity • Feb 10Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ₹245. The fair value is estimated to be ₹204, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 71%.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹238, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 57% over the past three years.
お知らせ • Dec 29Samrat Pharmachem Limited to Report Q3, 2026 Results on Feb 13, 2026Samrat Pharmachem Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Nov 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹842.1m market cap, or US$9.50m). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).
お知らせ • Mar 25Samrat Pharmachem Limited to Report Fiscal Year 2026 Results on May 30, 2026Samrat Pharmachem Limited announced that they will report fiscal year 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹1.49 loss per share (vs ₹9.01 profit in 3Q 2025)Third quarter 2026 results: ₹1.49 loss per share (down from ₹9.01 profit in 3Q 2025). Revenue: ₹638.3m (flat on 3Q 2025). Net loss: ₹4.60m (down 117% from profit in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
Buy Or Sell Opportunity • Feb 10Now 20% overvaluedOver the last 90 days, the stock has fallen 11% to ₹245. The fair value is estimated to be ₹204, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 71%.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹238, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 57% over the past three years.
お知らせ • Dec 29Samrat Pharmachem Limited to Report Q3, 2026 Results on Feb 13, 2026Samrat Pharmachem Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Nov 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹842.1m market cap, or US$9.50m). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).
New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹879.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 4.3% per year over the past 5 years. Market cap is less than US$10m (₹879.9m market cap, or US$9.97m). Minor Risk Paying a dividend despite having no free cash flows.
お知らせ • Sep 27Samrat Pharmachem Limited Appoints Piyush Dharod as Non-Executive Independent DirectorSamrat Pharmachem Limited at its AGM held on September 25, 2025, approved appointment of Mr. Piyush Dharod (DIN: 11119391) as Non-Executive Independent Director of the Company.
お知らせ • Sep 26Samrat Pharmachem Limited to Report Q2, 2026 Results on Nov 14, 2025Samrat Pharmachem Limited announced that they will report Q2, 2026 results on Nov 14, 2025
Upcoming Dividend • Sep 11Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 18 September 2025. Payment date: 24 October 2025. Payout ratio is a comfortable 4.3% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Aug 15First quarter 2026 earnings released: ₹0.74 loss per share (vs ₹6.69 profit in 1Q 2025)First quarter 2026 results: ₹0.74 loss per share (down from ₹6.69 profit in 1Q 2025). Revenue: ₹763.4m (down 6.2% from 1Q 2025). Net loss: ₹2.29m (down 111% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 02Samrat Pharmachem Limited Announces Resignation of Renu Dharod as Director, Effective 30 June 2025Samrat Pharmachem Limited announced that Ms. Renu Dharod (DIN: 07063088), has tendered her resignation as the Independent Director of the Company, with effect from close of business hours on 30th June, 2025, citing pre-occupation and other personal commitments. Consequently, she shall also cease to be the Chairman of the Corporate Social Responsibility Committee, Stakeholders Relationship Committee and Risk Management Committee and Member of the Audit Committee, Nomination & Remuneration Committee & Health, Safety and Sustainability Committee of the Company.
お知らせ • Jun 23Samrat Pharmachem Limited to Report Q1, 2026 Results on Aug 13, 2025Samrat Pharmachem Limited announced that they will report Q1, 2026 results on Aug 13, 2025
お知らせ • Jun 02Samrat Pharmachem Limited, Annual General Meeting, Sep 25, 2025Samrat Pharmachem Limited, Annual General Meeting, Sep 25, 2025.
New Risk • Jun 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.7m).
Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹23.02 (vs ₹7.00 in FY 2024)Full year 2025 results: EPS: ₹23.02 (up from ₹7.00 in FY 2024). Revenue: ₹2.87b (up 1.8% from FY 2024). Net income: ₹71.1m (up 229% from FY 2024). Profit margin: 2.5% (up from 0.8% in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
お知らせ • May 30Samrat Pharmachem Limited Recommends Dividend for Fiscal Year 2024-25, Payable on or Before October 24, 2025Samrat Pharmachem Limited at its meeting held on May 30, 2025 recommended Dividend at 10% on paid-up capital of the company. Record Date: September 18, 2025, The Company has fixed September 18, 2025, as the Record Date for the purpose of determining the Members eligible to receive dividend of INR 1.00 per equity share for Fiscal Year 2024-25. The dividend, if approved at the 33rd Annual General Meeting, shall be paid on or before October 24, 2025.
Valuation Update With 7 Day Price Move • May 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹390, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 26x in the Chemicals industry in India. Negligible returns to shareholders over past three years.
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹405, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 22% over the past three years.
お知らせ • Mar 26Samrat Pharmachem Limited to Report Fiscal Year 2025 Results on May 30, 2025Samrat Pharmachem Limited announced that they will report fiscal year 2025 results on May 30, 2025
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹386, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 16% over the past three years.
Reported Earnings • Feb 15Third quarter 2025 earnings released: EPS: ₹9.01 (vs ₹1.11 in 3Q 2024)Third quarter 2025 results: EPS: ₹9.01 (up from ₹1.11 in 3Q 2024). Revenue: ₹636.7m (up 3.2% from 3Q 2024). Net income: ₹27.8m (up ₹24.4m from 3Q 2024). Profit margin: 4.4% (up from 0.6% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 31Samrat Pharmachem Limited to Report Fiscal Year 2024 Results on Feb 14, 2025Samrat Pharmachem Limited announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Nov 16Second quarter 2025 earnings released: EPS: ₹8.61 (vs ₹0.61 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹8.61 (up from ₹0.61 loss in 2Q 2024). Revenue: ₹706.6m (down 11% from 2Q 2024). Net income: ₹26.6m (up ₹28.5m from 2Q 2024). Profit margin: 3.8% (up from net loss in 2Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Sep 27Samrat Pharmachem Limited to Report First Half, 2025 Results on Nov 14, 2024Samrat Pharmachem Limited announced that they will report first half, 2025 results on Nov 14, 2024
New Risk • Sep 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (1.2% net profit margin). Market cap is less than US$100m (₹1.71b market cap, or US$20.5m).
Buy Or Sell Opportunity • Sep 16Now 27% overvalued after recent price riseOver the last 90 days, the stock has risen 86% to ₹632. The fair value is estimated to be ₹498, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 33%.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹506, the stock trades at a trailing P/E ratio of 43.2x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 152% over the past three years.
お知らせ • Sep 04Samrat Pharmachem Limited Proposes Dividend for Fiscal Year 2023-24, Payable on or Before October 25, 2024Samrat Pharmachem Limited has fixed September 19, 2024, as the Record Date for the purpose of determining the Members eligible to receive dividend of INR 1.00/- per equity share for FY2023-24. The dividend, if approved at the 32nd Annual General Meeting, shall be paid on or before October 25, 2024.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹462, the stock trades at a trailing P/E ratio of 39.4x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 133% over the past three years.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹6.68 (vs ₹1.98 in 1Q 2024)First quarter 2025 results: EPS: ₹6.68 (up from ₹1.98 in 1Q 2024). Revenue: ₹814.1m (up 42% from 1Q 2024). Net income: ₹20.7m (up 238% from 1Q 2024). Profit margin: 2.5% (up from 1.1% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
お知らせ • Jul 05Samrat Pharmachem Limited Announces Director ResignationsSamrat Pharmachem Limited informed about the following changes composition of the Board: Mr. Mahendra Pipalia (DIN: 00216959), has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on 28th June, 2024, citing pre-occupation and other personal commitments. Consequently, he shall also cease to be the Chairman of the Audit Committee and Member of the Nomination & Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee, Corporate Social Responsibility Committee & Health, Safety and Sustainability Committee of the Company. Mr. Samir Kothary (DIN: 00216603), has tendered his resignation as the Independent Director of the Company, with effect from close of business hours on 28th June, 2024, citing pre-occupation and other personal commitments. Consequently, he shall also cease to be the Chairman of the Nomination & Remuneration Committee, Health, Safety and Sustainability Committee and Member of the Audit Committee, Stakeholders Relationship Committee, Risk Management Committee and Corporate Social Responsibility Committee of the Company.
お知らせ • Jun 30Samrat Pharmachem Limited to Report Q1, 2025 Results on Aug 13, 2024Samrat Pharmachem Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • Jun 04Full year 2024 earnings released: EPS: ₹7.00 (vs ₹53.83 in FY 2023)Full year 2024 results: EPS: ₹7.00 (down from ₹53.83 in FY 2023). Revenue: ₹2.83b (down 8.9% from FY 2023). Net income: ₹21.6m (down 87% from FY 2023). Profit margin: 0.8% (down from 5.4% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Declared Dividend • Jun 01Dividend of ₹1.00 announcedDividend of ₹1.00 is the same as last year. Ex-date: 19th September 2024 Payment date: 26th October 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (2% earnings payout ratio) and cash flows (5% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 98% to shift the payout ratio to a potentially unsustainable range, which is more than the 53% EPS decline seen over the last 5 years.
お知らせ • May 31Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024Samrat Pharmachem Limited, Annual General Meeting, Sep 26, 2024.
お知らせ • Mar 29Samrat Pharmachem Limited to Report Q4, 2024 Results on May 30, 2024Samrat Pharmachem Limited announced that they will report Q4, 2024 results at 3:30 PM, Indian Standard Time on May 30, 2024
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹1.11 (vs ₹6.78 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.11 (down from ₹6.78 in 3Q 2023). Revenue: ₹620.9m (down 26% from 3Q 2023). Net income: ₹3.44m (down 84% from 3Q 2023). Profit margin: 0.6% (down from 2.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Dec 30Samrat Pharmachem Limited to Report Q3, 2023 Results on Feb 14, 2024Samrat Pharmachem Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2024
Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹0.61 loss per share (vs ₹19.14 profit in 2Q 2023)Second quarter 2024 results: ₹0.61 loss per share (down from ₹19.14 profit in 2Q 2023). Revenue: ₹800.4m (up 13% from 2Q 2023). Net loss: ₹1.88m (down 103% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 27Samrat Pharmachem Limited to Report Q2, 2024 Results on Nov 08, 2023Samrat Pharmachem Limited announced that they will report Q2, 2024 results on Nov 08, 2023
Upcoming Dividend • Sep 11Upcoming dividend of ₹1.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 18 September 2023. Payment date: 24 October 2023. Payout ratio is a comfortable 1.9% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹418, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years.
Reported Earnings • Aug 15First quarter 2024 earnings released: EPS: ₹1.98 (vs ₹30.32 in 1Q 2023)First quarter 2024 results: EPS: ₹1.98 (down from ₹30.32 in 1Q 2023). Revenue: ₹578.4m (down 33% from 1Q 2023). Net income: ₹6.11m (down 94% from 1Q 2023). Profit margin: 1.1% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year whereas the company’s share price has increased by 57% per year.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹363, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 316% over the past three years.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹508, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 446% over the past three years.
お知らせ • Jul 01Samrat Pharmachem Limited to Report Q1, 2024 Results on Aug 14, 2023Samrat Pharmachem Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹53.83 (vs ₹55.62 in FY 2022)Full year 2023 results: EPS: ₹53.83 (down from ₹55.62 in FY 2022). Revenue: ₹3.11b (up 40% from FY 2022). Net income: ₹166.3m (down 3.2% from FY 2022). Profit margin: 5.3% (down from 7.7% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jun 01Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2023Samrat Pharmachem Limited at its board meeting held on May 30, 2023, recommended dividend of INR 1 per fully paid equity share of INR 10 each (10%) for the financial year ended March 31, 2023, subject to approval of the members at the upcoming Annual General Meeting of the Company.
お知らせ • May 31Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023Samrat Pharmachem Limited, Annual General Meeting, Sep 28, 2023. Agenda: Annual General Meeting.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹430, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 420% over the past three years.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹408, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 575% over the past three years.
Reported Earnings • Feb 18Third quarter 2023 earnings released: EPS: ₹6.78 (vs ₹20.87 in 3Q 2022)Third quarter 2023 results: EPS: ₹6.78 (down from ₹20.87 in 3Q 2022). Revenue: ₹839.9m (up 52% from 3Q 2022). Net income: ₹21.0m (down 68% from 3Q 2022). Profit margin: 2.5% (down from 12% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Dec 30Samrat Pharmachem Limited to Report Q4, 2022 Results on Feb 14, 2023Samrat Pharmachem Limited announced that they will report Q4, 2022 results at 3:30 PM, Indian Standard Time on Feb 14, 2023
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹869, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 842% over the past three years.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹768, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 697% over the past three years.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Independent Executive Director Megh Mehta was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 01Samrat Pharmachem Limited to Report Q2, 2023 Results on Nov 14, 2022Samrat Pharmachem Limited announced that they will report Q2, 2023 results on Nov 14, 2022
Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹1,156, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,286% over the past three years.
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹885, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 996% over the past three years.
お知らせ • Sep 03Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022Samrat Pharmachem Limited, Annual General Meeting, Sep 30, 2022, at 14:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹545, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 587% over the past three years.
お知らせ • Jul 01Samrat Pharmachem Limited to Report Q1, 2023 Results on Aug 13, 2022Samrat Pharmachem Limited announced that they will report Q1, 2023 results on Aug 13, 2022
Reported Earnings • Jun 01Full year 2022 earnings released: EPS: ₹55.62 (vs ₹17.26 in FY 2021)Full year 2022 results: EPS: ₹55.62 (up from ₹17.26 in FY 2021). Revenue: ₹2.22b (up 24% from FY 2021). Net income: ₹171.8m (up 222% from FY 2021). Profit margin: 7.7% (up from 3.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 31Samrat Pharmachem Limited Recommends Dividend for the Financial Year Ended March 31, 2022Samrat Pharmachem Limited recommended dividend of INR 1/- per fully paid equity share of INR 10/- for the financial year ended March 31, 2022, subject to approval of members at the upcoming annual general meeting of the company.
Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹431, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 412% over the past three years.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Non-Independent Executive Director Megh Mehta was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 09Samrat Pharmachem Limited to Report Q4, 2022 Results on May 30, 2022Samrat Pharmachem Limited announced that they will report Q4, 2022 results on May 30, 2022
Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹20.87 (up from ₹4.97 in 3Q 2021). Revenue: ₹553.4m (flat on 3Q 2021). Net income: ₹64.5m (up 320% from 3Q 2021). Profit margin: 12% (up from 2.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹426, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 608% over the past three years.
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹318, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 525% over the past three years.
Reported Earnings • Nov 18Second quarter 2022 earnings released: EPS ₹9.03 (vs ₹4.66 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹591.5m (up 43% from 2Q 2021). Net income: ₹27.9m (up 94% from 2Q 2021). Profit margin: 4.7% (up from 3.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹189, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 109% over the past three years.
Reported Earnings • Aug 18First quarter 2022 earnings released: EPS ₹3.09 (vs ₹2.58 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹473.9m (up 34% from 1Q 2021). Net income: ₹9.54m (up 20% from 1Q 2021). Profit margin: 2.0% (down from 2.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 30% per year.
Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹278, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 114% over the past three years.
Reported Earnings • Jul 03Full year 2021 earnings released: EPS ₹17.26 (vs ₹13.71 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹1.79b (up 30% from FY 2020). Net income: ₹53.3m (up 26% from FY 2020). Profit margin: 3.0% (down from 3.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 22% per year.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₹187, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 23% over the past three years.
Is New 90 Day High Low • Mar 01New 90-day high: ₹152The company is up 15% from its price of ₹133 on 01 December 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹145, the stock is trading at a trailing P/E ratio of 14.5x, up from the previous P/E ratio of 12.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years were flat.
Reported Earnings • Feb 14Third quarter 2021 earnings released: EPS ₹4.97 (vs ₹1.52 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹549.4m (up 56% from 3Q 2020). Net income: ₹15.4m (up 226% from 3Q 2020). Profit margin: 2.8% (up from 1.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Jan 14Samrat Pharmachem Limited to Report Q3, 2021 Results on Feb 13, 2021Samrat Pharmachem Limited announced that they will report Q3, 2021 results on Feb 13, 2021
お知らせ • Dec 05Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020Samrat Pharmachem Limited, Annual General Meeting, Dec 31, 2020, at 13:00 Indian Standard Time. Agenda: To consider and receive the audited financial statements of the company for the year ended 31 March 2020, together with directors' and auditors' reports thereon; to consider re-appointments of directors in place of Mr. Megh Rajesh Mehta (DIN: 07287394), who retires by rotation and, being eligible, offers himself for re-appointment; and to consider other matters.
Is New 90 Day High Low • Dec 01New 90-day high: ₹133The company is up 24% from its price of ₹107 on 02 September 2020. The Indian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Dec 01Market bids up stock over the past weekAfter last week's 15% share price gain to ₹133, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years are 67%.
Reported Earnings • Nov 16Second quarter 2021 earnings released: EPS ₹4.66The company reported a soft second quarter result with weaker earnings and profit margins, although revenues were improved. Second quarter 2021 results: Revenue: ₹415.2m (up 12% from 2Q 2020). Net income: ₹14.4m (down 4.2% from 2Q 2020). Profit margin: 3.5% (down from 4.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Market bids up stock over the past weekAfter last week's 16% share price gain to ₹130, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 11x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 81%.
お知らせ • Sep 09Samrat Pharmachem Limited to Report Q1, 2020 Results on Sep 14, 2020Samrat Pharmachem Limited announced that they will report Q1, 2020 results on Sep 14, 2020
お知らせ • Jul 18Samrat Pharmachem Limited to Report Fiscal Year 2020 Results on Jul 31, 2020Samrat Pharmachem Limited announced that they will report fiscal year 2020 results on Jul 31, 2020
